Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin
cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal
trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte
carcinoma in solid organ transplant recipients. This pilot trial will transition into the
pivotal trial if all feasibility targets are met.
Phase:
Phase 2
Details
Lead Sponsor:
Women's College Hospital
Collaborators:
Canadian Institutes of Health Research (CIHR) Natural Life Nutrition NOW Foods The Kidney Foundation of Canada